Hilco is delighted to offer for sale the business and assets of a cutting-edge company operating in the digital health and non-invasive diagnostics sector (the “Company”).
With over a decade of research and development, the Company has engineered a suite of patented, clinically validated wearable technologies for glucose monitoring and metabolic wellness. These non-invasive solutions are designed to revolutionise chronic disease management, offering a pain-free alternative to traditional continuous glucose monitors, combined with AI-driven digital health tools for real-time insights and behavioural change.
The Company has developed and commercialised a suite of innovative non-invasive health monitoring solutions, combining wearable medical devices with supporting digital health platforms. The Company’s products previously secured regulatory approval in multiple markets which have now lapsed, including CE mark certification in Europe.
This opportunity offers a unique chance for an acquirer to unlock value from mature, scalable, and commercially validated health tech assets.
No warranties, express or implied, are provided in relation to any information or statements made in connection to this opportunity. The information contained herein, and within the project dataroom, has not been verified by Hilco and prospective purchasers must undertake their own due diligence to satisfy themselves as to the accuracy of all such information and any statements made. Hilco’s full Terms and Conditions apply. Hilco acts as agent for the Vendor who offers for sale only such right, title and interest the Company possesses in the assets.
